ClinicalTrials.gg
CompletedNCT06678542Updated Mar 14, 2025

Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects

A Phase 1 interventional study of GP681 tablet and GP681 Powder for Oral Suspension in Healthy Participants, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

The primary objective is to evaluate the relative bioavailability and pharmacokinetic profile of a single oral dose of the test formulation, GP681 Powder for Oral Suspension (20 mg/sachet), compared to the reference formulation, GP681 tablet (20 mg/tablet), in healthy Chinese male subjects. The secondary objectives are to assess the safety of a single oral dose of the GP681 Powder for Oral Suspension (20 mg/sachet) and GP681 tablet (20 mg/tablet) in healthy Chinese male subjects, as well as the palatability (taste acceptability) of the GP681 Powder for Oral Suspension.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Jiangxi Qingfeng Pharmaceutical Co. Ltd. is the lead sponsor of 32 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: Healthy male subjects.
  2. Age: 18 to 45 years (inclusive).
  3. Body Weight: (BMI = weight (kg)/height2 (m2)) between 19.0 and 26.0 kg/m2 (inclusive), with body weight ≥ 50.0 kg.
  4. Taste Perception Ability: Successfully passed the taste perception ability test.
  5. : Fully understands the study's purpose, nature, requirements, methodology, and potential adverse reactions; voluntarily agrees to participate in the clinical trial and signs the informed consent form prior to any study procedures.
  6. : Subject (and their partner) has no plans to conceive or donate sperm from the time of first dosing until 3 months after the last dose and agrees to use effective contraception during this period.

Exclusion criteria

Exclusion Criteria:

  1. abnormalities, as determined by the investigator, including history of neurological, respiratory, cardiovascular, gastrointestinal, urinary, hematological and lymphatic, endocrine, musculoskeletal, or other disorders that could affect study results, or history of gastrointestinal disease within 3 months prior to screening.
  2. Inability to accurately express true taste perception.
  3. Dysfunction in taste or olfactory senses.
  4. Known or allergy to the product or any of its components (e.g., copovidone, crospovidone, lactose, microcrystalline cellulose, mannitol, maltitol, hydroxypropyl methylcellulose, colloidal silicon dioxide, sodium stearyl fumarate, sucralose, strawberry flavoring), or history of allergic diseases or a predisposition to allergies.
  5. Clinically significant abnormalities in vital signs, physical examination, clinical laboratory tests, 12-lead , or chest X-ray (posteroanterior view), or >450 ms, as assessed by the investigator.
  6. Positive test results for surface antigen (HBsAg), antibodies, Treponema pallidum antibodies, or antibodies.
  7. Smoking ≥10 cigarettes per day within 3 months prior to the first dose.
  8. Surgical procedure within 3 months before the first dose or planned surgery during the study period.
  9. Blood donation or significant blood loss ≥400 mL within 3 months before the first dose, or plans to donate blood within 3 months after the study.
  10. Participation in another clinical drug trial within 3 months before the first dose.
  11. Difficulty swallowing.
  12. Intolerance to skin puncture, fear of blood or needles, or poor venous access for blood sampling.
  13. Special dietary requirements or inability to adhere to the provided diet and study dietary restrictions.
  14. Positive urine drug screen, history of substance abuse within the past 5 years, or use of illicit drugs within 3 months before the first dose.
  15. Alcohol consumption exceeding 21 units per week (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine) within 6 months prior to screening, or a positive breath alcohol test.
  16. Use of any drugs known to inhibit or induce hepatic drug metabolism (e.g., inducers like barbiturates, carbamazepine, phenytoin, , omeprazole; inhibitors like SSRIs, cimetidine, diltiazem, macrolides, nitroimidazoles, sedatives, verapamil, fluoroquinolones, antihistamines) within 30 days before the first dose.
  17. Use of any prescription drugs, over-the-counter medications, herbal remedies, or supplements within 2 weeks prior to the first dose.
  18. Vaccination within 2 weeks before the first dose, or planned vaccination during the study.
  19. Consumption of foods or beverages rich in caffeine, poppy seeds, and/or theobromine, theophylline, or grapefruit (e.g., coffee, strong tea, chocolate, caffeinated carbonated drinks, cola, grapefruit juice) within 48 hours before the first dose, or engaging in vigorous exercise within 48 hours before the first dose.
  20. Any other condition deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treatment sequence T-R

    Drug: GP681 tablet · Drug: GP681 Powder for Oral Suspension

  • Experimental
    Treatment sequence R-T

    Drug: GP681 tablet · Drug: GP681 Powder for Oral Suspension

Interventions

  • DrugGP681Studies of GP681GP681 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GP681 tablet, 20 mg, single oral dose in each Group.

    Also known as: Reference treatment

  • DrugGP681Studies of GP681GP681 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GP681 Powder for Oral Suspension, 20 mg, single oral dose in each Group.

    Also known as: Test Treatment

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 360 hours post-dose

  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration[AUC(0-T)]

    Time frame: Up to 360 hours post-dose

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time[AUC(INF)]

    Time frame: Up to 360 hours post-dose

Secondary outcomes

  1. Time of maximum observed concentration(Tmax)

    Time frame: Up to 360 hours post-dose

  2. Apparent terminal half-life (T-HALF)

    Time frame: Up to 360 hours post-dose

  3. Incidence of adverse events (AEs)

    Time frame: Up to approximately 1 month post-dose

  4. Incidence of serious adverse events (SAEs)

    Time frame: Up to approximately 1 month post-dose

  5. Incidence of participants with vital sign abnormalities

    Time frame: Up to approximately 1 month post-dose

  6. Incidence of participants with physical examinations abnormalities

    Time frame: Up to approximately 1 month post-dose

  7. Incidence of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to approximately 1 month post-dose

  8. Incidence of participants with clinical laboratory abnormalities

    Time frame: Up to approximately 1 month post-dose

  9. Palatability Evaluation

    The palatability of GP681 Powder for Oral Suspension will be evaluated to characterize and quantify the sensory attributes of the product, such as basic tastes (including bitterness, astringency, sweetness) and texture (grittiness). Overall acceptability will also be assessed.

    Time frame: Up to 24 hours post-dose

07

Study locations

1 site
  • Women and Children's hospital of Ningbo University
    Ningbo, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Feb 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Nov 7, 2024
StartActual
Sep 27, 2024
Primary completionActual
Feb 16, 2025
CompletionActual
Feb 16, 2025
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06678542
Responsible party
Sponsor
First posted
Nov 7, 2024
Start date
Sep 27, 2024
Primary completion
Feb 16, 2025
Completion
Feb 16, 2025
Last update
Mar 14, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GP681

Start the discussion